Ron Squarer
Known title: DirectorCIK: 0001454001
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Transaction History
| ADCT | ▼ Sell | Tax Withholding | 15,196 | $47K | 6/3/2026 | View on chart |
| ADCT | ▲ Buy | Grant | 45,000 | $0 | 6/1/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 15,184 | $54K | 6/13/2025 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| ADCT | ▼ Sell | Open Market | 6,995 | $20K | 6/17/2024 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/13/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments
ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.